Heterogeneity of tumor endothelial cells and drug delivery

Kyoko Hida, Nako Maishi, Yu Sakurai, Yasuhiro Hida, Hideyoshi Harashima

Research output: Contribution to journalReview articlepeer-review

60 Citations (Scopus)


To date anti-angiogenic therapy has been used for cancer therapy widely, yielding promising results. However, it has been elucidated that current anti-angiogenic drug has several issues to be solved, such as side-effects and drug resistance. It has been reported that tumor endothelial cells (TECs) differ from normal counterparts. In addition, it was shown that the TECs are heterogeneous according to the malignancy status of tumor. The development of novel strategy for targeting tumor vasculature is required. Recently, we have developed an active targeting system, which targets TECs specifically. In this review, we will discuss how TECs in tumor vasculature are heterogeneous and offer new perspectives on a drug delivery system, which can target heterogeneous tumor blood vessels from a viewpoint of personalized medicine.

Original languageEnglish
Pages (from-to)140-147
Number of pages8
JournalAdvanced Drug Delivery Reviews
Publication statusPublished - 2016 Apr 1
Externally publishedYes


  • Angiogenesis
  • Anti-angiogenic therapy
  • Drug delivery
  • Heterogeneity
  • MEND
  • Metastasis
  • Tumor
  • Tumor endothelial cell

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Heterogeneity of tumor endothelial cells and drug delivery'. Together they form a unique fingerprint.

Cite this